vixarelimab (RG6536) / Roche, Kiniksa  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vixarelimab (RG6536) / Roche
NCT03858634: A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Completed
2
58
US
KPL-716, vixarelimab, Placebo
Kiniksa Pharmaceuticals, Ltd.
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
04/20
06/20
KPL-716-C201, NCT03816891 / 2020-004198-38: Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Completed
2
190
Europe, Canada, US, RoW
vixarelimab, KPL-716, Placebo
Kiniksa Pharmaceuticals, Ltd.
Prurigo Nodularis, Pruritis
12/22
08/23
NCT06137183: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Recruiting
2
210
Europe, US, RoW
Vixarelimab, RO7622888; KPL-716, Placebo
Genentech, Inc.
Ulcerative Colitis
09/26
05/27
NCT05785624: A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Recruiting
2
320
Europe, Canada, US, RoW
Vixarelimab, RO7622888, KPL-716, Placebo
Genentech, Inc.
Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
04/27
08/27

Download Options